Elan Reaffirms Positive Outlook for Remainder of 2000 and Calendar Year 2001

Search Blogs that Mention this News Release

Click this link to view linked Bookmarking Services

Click this link to view linked Blogging Services

Elan Reaffirms Positive Outlook for Remainder of 2000 and Calendar Year 2001

    DUBLIN, Ireland, Dec. 21 /PRNewswire/ -- Elan Corporation, plc (NYSE: ELN)
("Elan") states that it knows of no reason for the recent decline of its share
price and that it remains comfortable with the high end of consensus estimates
for the fourth quarter and year-end 2000 and calendar year 2001.
    In addition, Elan confirms that all of its major development programs and
new product introductions are on track.
    Elan Corporation, plc is a leading worldwide specialty pharmaceutical and
drug delivery company headquartered in Ireland, with its principal research,
development, manufacturing and marketing facilities located in Ireland, the
United States and Israel. Elan is focused on the discovery, development and
marketing of therapeutic products and services in neurology, pain management
and oncology, and on the development and commercialization of products using
its extensive range of proprietary drug delivery technologies. Elan shares
trade on the New York, London and Dublin Stock Exchanges.

SOURCE Elan Corporation, plc

http://www.elan.ie
Company News On-Call:

http://www.prnewswire.com/comp/231593.html or fax,
800-758-5804, ext. 231593
CONTACT:
Investors - U.S.: Jack Howarth, 212-407-5740
or 800-252-3526, Europe - Emer Reynolds, +353-1-709-4000 or
+00800-28352600; Media - Max Gershenoff, 212-407-5740 or
800-252-3526, all of Elan Corporation, plc